Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Adverse events were consistent with valbenazine’s established safety profile
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
NUFYMCO BLA has been approved by the USFDA
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
Subscribe To Our Newsletter & Stay Updated